sulfamethoxazole + trimethoprim + minocycline

This is a combination of three antibiotics—sulfamethoxazole, trimethoprim, and minocycline. Sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid (PABA) in the biosynthesis of dihydrofolate. Trimethoprim is an antifolate that inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for DNA and protein synthesis. Minocycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit and preventing aminoacyl-tRNA from attaching to the ribosome. The combination targets multiple pathways in bacteria—nucleic acid/protein biosynthesis (via folate pathway inhibition) and direct inhibition of protein synthesis—potentially providing broad-spectrum antibacterial activity[3][4]. This specific triple combination does not have an established brand name or widespread clinical use as a fixed-dose product but may be used experimentally or off-label for certain resistant infections.

Other names

SXT + minocyclineTMP-SMX + minocycline